Optiver Holding’s Esperion Therapeutics ESPR Stock Holding History

Optiver Holding’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$796	Sell	252 -2,947	-92%	-$8.24K	﹤0.01%	2530
2026 Q1	$8.77K	Buy	3,199 +1,981	+163%	+$6.27K	﹤0.01%	1248
2025 Q4	$4.51K	Sell	1,218 -729	-37%	-$2.36K	﹤0.01%	1443
2025 Q3	$5.16K	Sell	1,947 -1	-0.1%	-$2	﹤0.01%	1712
2025 Q2	$1.92K	Sell	1,948 -3,981	-67%	-$3.99K	﹤0.01%	1349
2025 Q1	$8.54K	Buy	5,929 +3,558	+150%	+$6.56K	﹤0.01%	939
2024 Q4	$5.22K	Buy	2,371 +799	+51%	+$1.86K	﹤0.01%	854
2024 Q3	$2.59K	Buy	+1,572	New	+$3.17K	﹤0.01%	846

Other funds holding ESPR

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Optiver Holding's ESPR Position: Q2 2026 in Review

Optiver Holding reduced its Esperion Therapeutics (ESPR) stake by 92% in Q2 2026, selling an estimated $8.24K and leaving 252 shares worth $796. The position accounts for ﹤0.01% of the portfolio, ranked #2530.

Optiver Holding first reported a position in ESPR in Q3 2024 and has held it in 8 quarters since. The position peaked at $8.77K in Q1 2026. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

Optiver Holding held 252 shares of Esperion Therapeutics worth $796 as of Q2 2026.
Optiver Holding sold 2,947 Esperion Therapeutics shares in Q2 2026, an estimated $8.24K.
Esperion Therapeutics made up ﹤0.01% of Optiver Holding's portfolio in Q2 2026, its #2530 holding.
Optiver Holding first reported a position in Esperion Therapeutics in Q3 2024 and has held it in 8 quarters since.
Optiver Holding's Esperion Therapeutics position peaked at $8.77K in Q1 2026.
191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.